Veterinary Cardiology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type (Companion Animals, Production Animals), By Product (Pharmaceuticals, Diagnostics), By Indication (Congestive Heart Failure, Myocardial Disease, Arrythmias, Others), By End Use (Veterinary Hospitals & Clinics, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.83 Billion
CAGR (2026-2031)	8.86%
Fastest Growing Segment	Companion Animal
Largest Market	North America
Market Size (2031)	USD 4.71 Billion

Market Overview

The Global Veterinary Cardiology Market will grow from USD 2.83 Billion in 2025 to USD 4.71 Billion by 2031 at a 8.86% CAGR. Veterinary cardiology comprises the specialized diagnostic instruments, pharmaceuticals, and therapeutic interventions designed to detect and manage cardiovascular disorders in companion animals. The market expansion is fundamentally supported by the rising prevalence of geriatric heart conditions in pets and the deepening human-animal bond that compels owners to seek advanced medical treatments. According to the American Pet Products Association, in 2024, total expenditure in the veterinary care and product sales category reached $39.8 billion. This substantial financial investment underscores the robust economic foundation enabling veterinary practices to incorporate dedicated cardiac services and advanced diagnostic modalities.

Despite these strong growth drivers, the market faces a significant impediment regarding the high costs associated with specialized cardiac care. The substantial capital required for acquiring advanced echocardiography systems and the expenses related to complex surgical procedures often limit accessibility for financially constrained pet owners. This economic barrier restricts the potential patient base and may hamper the widespread adoption of premium cardiology solutions in price sensitive regions.

Key Market Drivers

Technological advancements in veterinary cardiac diagnostics and imaging are fundamentally reshaping the market by enabling earlier and more accurate detection of complex heart conditions. Innovations in echocardiography, electrocardiogram (ECG) monitoring, and biomarker analysis allow veterinarians to diagnose issues such as mitral valve disease before clinical signs become severe. The integration of artificial intelligence into these diagnostic tools further enhances clinical decision-making, driving higher adoption rates of diagnostic equipment in practices. According to IDEXX Laboratories, October 2024, in the 'Third Quarter Results', the company achieved a 10% annual growth in its global premium instrument installed base, reflecting this surge in diagnostic capability. Additionally, according to Nationwide, April 2024, in the 'Most Common Medical Conditions' report, valvular heart disease ranked as the eighth most common medical condition affecting dogs, reinforcing the critical need for these precise detection methods.

Expansion of pet insurance coverage is improving access to specialty care, serving as a vital financial bridge for pet owners facing the high costs of long-term cardiac management. As insurance policies increasingly cover chronic conditions and specialist referrals, owners are more empowered to pursue expensive life-prolonging treatments, such as pacemaker implantations or lifelong pharmaceutical regimens, which were previously cost-prohibitive. This financial protection directly fuels revenue growth for specialty cardiology clinics and pharmaceutical manufacturers. According to the North American Pet Health Insurance Association, April 2024, in the 'State of the Industry Report 2024', the sector recorded $4.27 billion in total premiums sold in 2023, indicating a substantial increase in the resources available for funding advanced veterinary healthcare.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the growth of the Global Veterinary Cardiology Market is the high cost associated with specialized cardiac care. Advanced diagnostic instruments like echocardiography systems and complex therapeutic interventions require significant capital investment from veterinary practices. To recoup these expenditures, clinics must set higher service fees, which often places a heavy financial burden on pet owners. This economic pressure makes specialized cardiac procedures inaccessible for many, particularly in regions where pet insurance penetration is low or for owners with limited disposable income.

This financial barrier directly restricts the addressable patient base and limits the widespread adoption of premium cardiology solutions. When the cost of care exceeds what owners can afford, they are frequently forced to decline or delay critical treatments, which reduces the overall volume of cardiac services utilized. According to the American Veterinary Medical Association, in 2024, veterinary practices experienced a 2.3% decrease in patient visits driven primarily by rising prices. This decline in engagement indicates that escalating costs are actively preventing a segment of the market from accessing available veterinary services, thereby stalling the sector's potential for broader expansion.

Key Market Trends

The Advancement of Minimally Invasive Interventional Procedures is fundamentally transforming the market by providing safer, catheter-based alternatives to high-risk open-heart surgeries. Veterinarians are increasingly adopting sophisticated techniques, such as transcatheter edge-to-edge repair, to treat complex conditions like mitral valve disease, which significantly reduces recovery times and surgical trauma for geriatric pets. This clinical shift toward high-value modalities is driving a measurable surge in the utilization and expense of specialized cardiac care. According to Trupanion, July 2025, in the 'Countering the Costs Amid a Growing Divide in Pet Care' report, the volume of cardiology claims for dogs increased by 55% over the analyzed period, while the average claim amount rose by 34%, reflecting the robust market migration toward these advanced interventional services.

Simultaneously, the Adoption of Tele-cardiology and Remote Consulting Services is accelerating, enabling general practitioners to bridge the diagnostic gap through seamless access to cardiac specialists. This model relies heavily on integrated cloud-based ecosystems that facilitate the immediate transmission of echocardiograms and electrocardiogram data for remote expert interpretation, necessitating substantial investment in digital infrastructure. The momentum behind this connected care approach is directly influencing the revenue streams of diagnostic technology providers. According to IDEXX Laboratories, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', revenue from veterinary software, services, and diagnostic imaging systems increased by 13% on a reported basis, underscoring the critical role of digital platforms in supporting the expanding tele-cardiology workflow.

Segmental Insights

The Companion Animal segment constitutes the fastest-growing category in the Global Veterinary Cardiology Market, fueled by rising pet ownership and the pervasive trend of pet humanization. As owners increasingly regard animals as integral family members, there is a marked surge in expenditure on specialized healthcare for age-related cardiac conditions. This growth is bolstered by advancements in diagnostic technologies and the approval of innovative therapeutic solutions by agencies such as the U.S. Food and Drug Administration. Consequently, the demand for timely detection and management of cardiovascular diseases in dogs and cats continues to accelerate market expansion.

Regional Insights

North America maintains a leading position in the global veterinary cardiology market, driven by the rising prevalence of cardiovascular diseases among companion animals and high per capita expenditure on veterinary care. The region benefits from a well-established infrastructure for animal health and widespread awareness regarding early diagnosis. Furthermore, the presence of major pharmaceutical companies and strictly regulated approval processes by the U.S. Food and Drug Administration ensure the availability of effective treatments. These factors, combined with strong support from the American Veterinary Medical Association for clinical standards, sustain regional market dominance.

Recent Developments

• In September 2025, Dechra Veterinary Products launched a new digital educational tool designed to assist veterinarians in communicating complex cardiac conditions to pet owners. The company introduced a 4D heart model that visually demonstrated the progression of myxomatous mitral valve disease, the most prevalent heart condition in dogs. This innovative resource was developed to clearly illustrate the structural changes occurring in the heart valves and chambers across the four stages of the disease. The launch aimed to enhance client understanding and compliance with monitoring and treatment protocols, addressing a key challenge in the long-term management of chronic heart failure.
• In June 2025, Boehringer Ingelheim entered into a strategic collaboration with Eko Health to develop advanced diagnostic capabilities for veterinary cardiology. The partnership combined the pharmaceutical company's extensive expertise in canine heart health with the partner's proprietary artificial intelligence algorithms and digital stethoscope technology. The initiative focused on creating a canine-specific detection algorithm capable of identifying heart murmurs with high accuracy during routine physical examinations. This breakthrough research effort was established to equip veterinary professionals with a powerful screening tool to detect myxomatous mitral valve disease earlier, thereby facilitating timely intervention and improved quality of life for dogs.
• In October 2024, Ceva Santé Animale announced a strategic partnership with an emerging technology developer following the conclusion of its annual innovation challenge. The animal health leader selected WithApet AI as a key collaborator to advance the early detection of heart disease in companion animals. This collaboration aimed to integrate artificial intelligence into veterinary cardiology, supporting the development of non-invasive diagnostic tools that can identify cardiac issues before clinical symptoms manifest. By fostering this external innovation, the company reinforced its commitment to expanding its cardiology portfolio with digital health solutions that improve long-term patient monitoring and care.
• In May 2024, Vetoquinol USA Inc. received conditional approval from the U.S. Food and Drug Administration for a new therapeutic option designed to manage congestive heart failure in canine patients. The approved product, UpCard-CA1, became the first torsemide oral solution specifically indicated for the treatment of pulmonary edema caused by myxomatous mitral valve disease. This development provided veterinarians with a potent loop diuretic alternative to furosemide, intended for concurrent use with other cardiac medications such as pimobendan and spironolactone. The conditional approval allowed the company to make the treatment available while continuing to collect effectiveness data for a full application.

Key Market Players

• Boehringer Ingelheim International GmbH
• Jurox Pty Limited
• Ceva Animal Health, LLC
• Merck & Co., Inc.
• IDEXX
• Apex Bio Medicals
• SOUND
• GE HealthCare
• FUJIFILM Holdings America Corporation
• ESAOTE SPA

By Animal Type	By Product	By Indication	By End Use	By Region
Companion Animals Production Animals	Pharmaceuticals Diagnostics	Congestive Heart Failure Myocardial Disease Arrythmias Others	Veterinary Hospitals & Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Cardiology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Cardiology Market, By Animal Type:

• Companion Animals
• Production Animals

• Veterinary Cardiology Market, By Product:

• Pharmaceuticals
• Diagnostics

• Veterinary Cardiology Market, By Indication:

• Congestive Heart Failure
• Myocardial Disease
• Arrythmias
• Others

• Veterinary Cardiology Market, By End Use:

• Veterinary Hospitals & Clinics
• Others

• Veterinary Cardiology Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE